Internal jugular vein thrombosis by protein C activated resistance
Tài liệu tham khảo
Dahlback B, Garisson M, Svensson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90:1004–08.
Bounameaux, 2000, Factor V Leiden paradox: risk of deep vein thrombosis but not of pulmonary embolism, Lancet, 356, 182, 10.1016/S0140-6736(00)02476-4
Jadaon, 2010, High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait, Diagn Mol Pathol, 19, 180, 10.1097/00019606-201009000-00009
Bouslama, 1997, Frequence de la resistance à la proteine C activée à Tunis, Rev Med Interne, 18, 520, 10.1016/S0248-8663(97)80036-7
Bertina, 1994, Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature, 369, 64, 10.1038/369064a0
Haute Autorité de santé. Test de résistance à la protéine C activée. Recherche de la mutation Facteur V Leiden. 2006, Téléchargeable sur le site: www.has-sante.fr.
Blom, 2005, Malignancies, prothrombotic mutation, and the risk of venous thrombosis, JAMA, 293, 715, 10.1001/jama.293.6.715
Walker, 2001, Investigation and management of heritable thrombophilia. Guideline, Br J Haematol, 114, 512, 10.1046/j.1365-2141.2001.02981.x
Marchiori, 2007, The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies, Haematologica, 92, 1107, 10.3324/haematol.10234